Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + nimotuzumab
- Development stage
- Phase 2
- Lead developer
- Biotech Pharmaceutical Corp
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of docetaxel, a taxane chemotherapy agent that disrupts cell division by stabilizing microtubules, and nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). This combination has been studied in various cancer types including head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), and non-small-cell lung cancer (NSCLC).
02
Targets
EGFR (Epidermal growth factor receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + nimotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + nimotuzumab.